BackArcus Biosciences Overview
Arcus Biosciences Inc

Arcus Biosciences Target Price

Where could RCUS trade next? Consensus target price: $39.

Get informed when a big investor buys or sells

+ Follow

Share Price

$28.72

Average Target Price

$39.0035.8% upside

6 analysts in the last 4 months

High: $47 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Goldman SachsRichard Law$4246.2% upsideOpen
2026-08-06Wedbush$4349.7% upsideOpen
2026-07-20H.C. WainwrightEmily Bodnar$4556.7% upsideOpen
2026-05-18Truist Financial$3521.9% upsideOpen
2026-05-11Morgan Stanley$2223.4% downsideOpen
2026-04-20Leerink Partners$4763.6% upsideOpen
2026-02-12Wells Fargo$2319.9% downsideOpen
2026-01-12Goldman SachsRichard Law$282.5% downsideOpen
2026-01-08Morgan Stanley$2030.4% downsideOpen
2025-12-12Truist Financial$304.5% upsideOpen
2025-12-12H.C. Wainwright$3211.4% upsideOpen
2025-10-30Goldman SachsSalveen Richter$1644.3% downsideOpen
2025-10-29Wedbush$3521.9% upsideOpen
2025-10-29H.C. Wainwright$282.5% downsideOpen
2025-10-07Truist FinancialAsthika Goonewardene$3935.8% upsideOpen
2025-05-07Wells FargoEva Fortea Verdejo$269.5% downsideOpen
2024-10-24CitigroupYigal Nochomovitz$4660.2% upsideOpen
2024-10-21H.C. WainwrightEmily Bodnar$2030.4% downsideOpen
2024-10-08Wells FargoEva Fortea Verdejo$291% upsideOpen
2024-10-08Morgan StanleyJudah Frommer$3521.9% upsideOpen
2024-08-09Bank of America SecuritiesJason Zemansky$2319.9% downsideOpen
2024-07-08BarclaysPeter Lawson$2513% downsideOpen
2024-06-24Truist FinancialAsthika Goonewardene$4453.2% upsideOpen
2024-06-04BarclaysPeter Lawson$3521.9% upsideOpen
2022-12-20Citigroup$4246.2% upsideOpen
2022-11-23Citigroup$3728.8% upsideOpen
2022-05-11WedbushRobert Driscoll$4246.2% upsideOpen

Arcus Biosciences (RCUS) FAQ

As of the most recent data, RCUS shows a target price of $39. Scroll down for historical charts and peer comparison views.

If Arcus Biosciences moved to the average analyst target of $39, shares would be roughly 35.8% higher than $28.72. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Arcus Biosciences's earnings trajectory.

Besides this target price page, Stockcircle has Arcus Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $39) with ownership activity and broader fundamentals.

Arcus Biosciences's target price is $39; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.